July 7 (Reuters) - has agreed to buy for about $10 billion, expanding its reach beyond blood disorders and pain into rare endocrine diseases.

The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology and neurology to rare diseases and obesity.

Below are some of the major deals involving U.S.-based pharma and biotech firms from the past decade:

Year Acquirer Target Deal Description

Value

2026 Vertex Crinetics About $10 To expand its

Pharmaceuticals Pharmaceu billion portfolio in

ticals rare hormonal

diseases

2026 $11.3 To expand its

ne billion presence in

the life

sciences

market with

access to

research and

bioprocessing

tools

2026 Apogee $10.9 To expand

Therapeut billion immunology

ics pipeline

2026 $10.6 To expand

billion late-stage

cancer drug

pipeline

2026 Boston $14.5 To expand

Scientific billion vascular

pipeline

2025 Abbott () Exact up to $23 To gain

Sciences billion access to

Exact

Sciences’

cancer tests,

including

flagship

colorectal

cancer test

Cologuard 

2025 Merck  Cidara $9.2 To gain

Therapeut billion access to

ics  Cidara’s

experimental

drug for flu

prevention

2025   Metsera  $10 To gain a

billion foothold in

the

fast-growing

obesity

treatment

market

2025  Merck & Co  Verona About $10 Strengthens

Pharma  billion Merck’s

respiratory

portfolio

amid looming

Keytruda

patent cliff

2025 Johnson & Intra-Cel $14.6 Expands J&J’s

Johnson  lular billion footprint in

Therapies brain disease

treatments

2024 Novo Holdings Catalent  $16.5 Boosts

billion manufacturing

(includin capacity for

g debt), Novo

$11.5 Nordisk’s

billion popular

(excludin obesity drug

g debt) Wegovy

2023 Merck & Co  Prometheu $10.8 Adds

s billion experimental

Bioscienc treatment for

es ulcerative

colitis and

Crohn’s

disease and

builds up

presence in

immunology

2023 Bristol Myers Karuna $14 BMY gains a

Squibb Therapeut billion promising

ics antipsychotic

medicine as

patents on

its older

therapies

near their

expiry

2023 Pfizer  Seagen $43 Builds

billion Pfizer’s

cancer

portfolio

amid decline

in sales for

COVID-related

products and

generic

competition

2022   Horizon $27.8 Buyout,

Therapeut billion biggest in

ics the sector in

2022,

fortifies

rare diseases

portfolio

2022 Pfizer  Biohaven $11.6 Pfizer bets

Pharmaceu billion big on a new

tical class of

Holding migraine

drugs

2021 Merck & Co Acceleron About Diversifies

Pharma  $11.5 Merck’s

billion portfolio

beyond

cancer 

2021 Soaring $17.5 Ginkgo goes

Eagle billion public

Acquisiti through a

on merger with a

blank-check

vehicle

backed by

former

Hollywood

executives

Harry Sloan

and Jeff

Sagansky

2020   Alexion $39 AstraZeneca’s

Pharmaceu billion largest-ever

ticals deal to

diversify

away from its

cancer

business,

betting on

rare-disease

and

immunology

drugs

2020 Bristol Myers MyoKardia About $13 Bolsters

Squibb   billion Bristol’s

portfolio of

heart disease

treatments

2020   Immunomed $21 Strengthens

ics  billion Gilead’s

cancer

portfolio 

2019 Mylan Pfizer’s About $12 Mylan’s

Upjohn billion acquisition

business of Pfizer’s

Upjohn

business was

structured as

a stock-based

merger,

resulting in

the formation

of .

Upjohn was

essentially

spun off to

Pfizer

shareholders

and then

merged with

Mylan 

2019 AbbVie  Allergan  $63 AbbVie gains

billion, control of

$83 Botox and

billion diversifies

(includin its portfolio

g debt) beyond its

then-blockbus

ter drug,

Humira 

2019 Pfizer Array $11.4 Pfizer gains

Biopharma billion oncology

asset 

2019 Bristol Myers Celgene $74 One of the

Squibb Corp billion largest

pharmaceutica

l mergers in

history 

2017 Johnson & Actelion $30 Johnson &

Johnson  billion Johnson’s

subsidiary,

Janssen

Holding,

acquires

Actelion;

Actelion’s

R&D unit spun

off into

Idorsia

2017 Gilead Kite $11.9 Strengthens

Sciences   Pharma billion Gilead’s

position in

the field of

cell therapy,

particularly

in CAR-T

treatments

for cancer 

2016  Pfizer Medivatio $14 Pfizer

n billion acquires

blockbuster

prostate

cancer drug

Xtandi 

2015 Shire Baxalta $32 Catapults

billion Shire to

leading

position in

treating rare

diseases

2015 AbbVie Pharmacyc $21 AbbVie gets

lics billion access to

what is

expected to

be one of the

world’s

top-selling

cancer drugs

and expands

its reach in

the

profitable

oncology

field

2015 Valeant Salix $14.5 Makes Valeant

Pharmaceuticals Pharmaceu billion a leader in

(now Bausch ticals gastrointesti

Health)  nal drugs 

2015 Pfizer Hospira $15 Deal creates

billion leading

global

established

pharmaceutica

l business

for Pfizer